ABOUT US
OUR SCIENCE
OUR TEAM
PARTNERING
INVESTMENTLATEST NEWSCAREERS
GET IN TOUCH
About Us
Our Science
Oncology
Chronic Diseases
Pipeline
Our Team
partnering
Business Development
Scientific Collaboration
Investment
Latest News
Careers
GET IN TOUCH
ABOUT US
OUR SCIENCE
OUR TEAM
PARTNERING
INVESTMENTLATEST NEWSCAREERS
GET IN TOUCH

Latest News

Keep up to date with the latest news from Pilatus Biosciences.

News

February 19, 2026

Pilatus Biosciences Receives FDA Fast Track Designation for Metabolic Checkpoint Inhibitor PLT012 in Hepatocellular Carcinoma

December 15, 2025

Pilatus Biosciences Announces FDA Clearance of IND Application for PLT012, a First-in-Class Anti-CD36 Metabolic Checkpoint Antibody in Solid Tumors

December 8, 2025

Pilatus Biosciences is Selected for LabCentral New Cambridge-Based Educational Program

October 30, 2025

Pilatus Biosciences to Present New Preclinical Data Highlighting PLT012’s Ability to Induce Durable Anti-Tumor Immunity Through Immunometabolic Reprogramming of the Tumor Microenvironment at SITC 2025 Annual Meeting

Press Articles

Yahoo Finance

Pilatus Biosciences Announces Formation of Scientific Advisory Board

Leading experts in immunometabolism, immunology, and liver disease to guide advancement of metabolic checkpoint therapies

May 5, 2026

BioWorld

Pilatus PLT-012 takes immunometabolic approach to reprogram TME

Pilatus Bio Inc. is working to address a major under-addressed target of current checkpoint inhibitors: metabolic stress within solid tumors.

April 28, 2026

Startupticker.ch

Swiss biotechs advance clinical programs across multiple therapeutic areas

Five biotech companies announced recent developments ranging from FDA Fast Track and Orphan Drug designations to the start of Phase 1 and Phase 3 clinical trials. The updates highlight progress in oncology, rare blood disorders, neurodegenerative diseases, multidrug-resistant infections, and Duchenne muscular dystrophy.

March 19, 2026

CancerNetwork

FDA Grants Fast Track Designation to PLT012 for Advanced Liver Cancer

A phase 1 trial evaluating PLT012 in HCC, among other solid tumors, is currently underway and will report safety and preliminary clinical activity data.

February 20, 2026

Upcoming Events

June 21, 2026

-

June 21, 2026

San Diego

BayHelix Global Biotech Leaders Forum

More Info

June 23, 2026

-

June 23, 2026

EHL, Lausanne

DO Retreat

More Info

June 24, 2026

-

San Diego

BIO International Convention San Diego

More Info

Unlocking Immune Potential with
Innovative Metabolic Reprogramming

Pilatus Biosciences

Pilatus Biosciences SA
Route de la Corniche 6
1066 Epalinges
Vaud - SWITZERLAND
Pilatus Biosciences Corp
17F-1, No. 508, Section 7,
Zhongxiao East Road,
Nangang District, 
Taipei City 115, Taiwan
info@pilatusbio.com

Links

AboutOncologyChronic DiseasesPipelineOur TeamBusiness
DevelopmentScientific
CollaborationLatest NewsCareers

© 2025 Pilatus Biosciences. All Rights Reserved.

Privacy Policy